Migraine Drugs Market Report Scope & Overview:
The migraine drugs market was valued at USD 6.59 billion in 2024 and is expected to reach USD 15.54 billion by 2032, growing at a CAGR of 11.34% over the forecast period of 2025-2032.
The global migraine drug markets are growing ever faster with the advent of alternatives that target CGRP monoclonal antibodies or gepants. The answer is that these therapies are more effective, better tolerated, and provide targeted relief, particularly for patients who don't respond to traditional medications, including triptans. This migraine drugs market trend underscores a pivot towards mechanism-based innovation, improved patient adherence, and an embracing of higher costs on a global scale. The trend, of course, perpetuates R&D investment, enriching its treatment diversity and boosting the market by advancing to unmet needs in migraine prevention and acute care.
For instance, in February 2025, Pfizer reported USD 835 million in 2024 global sales of Nurtec ODT, marking a 35% growth driven by CGRP therapy adoption.
The U.S. migraine drugs market was valued at USD 2.47 billion in 2024 and is expected to reach USD 5.80 billion by 2032, growing at a CAGR of 11.26% over 2025-2032.
The U.S. leads migraine drugs market due to its strong base for the pharmaceutical industry with high R&D, FDA approvals with efficiency, and high health care penetration. The high level of healthcare expenditure, targeted investment, and an innovation culture drive the pace of development and access to CGRP-targeted treatments. This champion analysis demonstrates how the US ecosystem fosters fast commercialization, rendering the country the most attractive pathway to launch innovative migraine drugs and expand the market over time.
For instance, in December 2024, IQVIA reported that the U.S. contributed over 63% of global CGRP migraine drug sales, led by AbbVie, Pfizer, and Eli Lilly.
Market Dynamics:
Drivers:
-
Rise of Fast-Acting Migraine Medications is Driving the Migraine Drugs Market Growth
Growing fast-acting migraine medications are the major drivers as they increase patient adherence, satisfaction & clinical outcomes for migraine drugs market. Such therapies address immediate symptom alleviation needs, driving adoption and growing the patient population. The effectiveness and convenience justify high pricing and innovation. This dynamic has a substantial impact on the migraine drugs market share. When the market leaders have drugs that work fast, such drug companies can win a competitive edge and drive the market further with R&D.
For instance, in November 2024, the Migraine Research Foundation reported that 64% of patients preferred fast-acting migraine therapies, citing quicker relief and improved post-dose functionality.
Restraints:
-
Side Effects and Dependency Risks Are a Significant Restraint on the Migraine Drugs Market Growth
Side effects and dependency risks remain significant barriers to the migraine drugs market growth by lowering patient compliance, constraining physician prescribing, and resulting in regulatory and reimbursement issues. Nothing is widely adopted over concerns about safety, particularly with opioids or drugs that don’t sit well with patients. Such risks impede public perception and market entry, which is hampering the growth of the migraine drugs market despite market innovation. Safety and tolerability are clearly still critical to tapping into the greater market.
For instance, in September 2024, the CDC reported that 14% of migraine patients discontinued their medication due to side effects, especially over triptans and older antidepressant-based treatments.
Segmentation Analysis:
By Treatment
Preventive is the dominant segment in the global migraine drugs market, with a 61.06% market share in 2024, owing to increasing use of CGRP monoclonal antibodies and gepants that reduce attack frequency and severity. Increasing awareness, improved patient compliance, and the necessity of handling chronic migraine in the long term are factors. Preventive treatments are increasingly favoured by doctors to enhance treatment outcomes and diminish reliance on emergency care.
The acute segment is emerging as the fastest growing, with a CAGR of 11.05% in the migraine drugs market, fueled by more people with episodic migraines being diagnosed. Developments including gepants and nasal sprays provide fast symptom relief with fewer side effects than triptans. Patients' desire for rapid relief and better tolerance of the drugs were major factors that have been driving growth in this segment.
By Route of Administration
In 2024, the injectables dominated the ophthalmic lasers industry with a 68.76% market share, owing to the increasing use of CGRP monoclonal antibodies including Aimovig, Ajovy, and Emgality for preventive therapy. These long-acting injectables deliver a dose once a month or once per quarter, and their use has been shown to increase compliance while cutting the frequency of migraines. Proven effectiveness, ease of use, and expanding physician acceptance are likely to support wide adoption and the continued dominance of these drugs in the marketplace.
The Oral segment is the fastest growing aspect of the Migraine Drugs Market analysis, as the use of CGRP receptor antagonists including Nurtec ODT and Qulipta grows. These well-tolerated, non-invasive interventions may be used both acutely and prophylactically. Increased patient convenience, quicker onset of action, and lower adverse effects vs. older oral therapies are among the factors driving rapid expansion of this segment.
By Age
Pediatric held a dominant migraine drugs market share of 60.40% of the migraine drugs industry in 2024, driven by migraines are increasingly common in children and teenagers. The demand is driven by early diagnosis, parental awareness, and progress in formulation required for different age groups. Child neurologists are more and more involved in preventive and urgent treatments according to the recent approval for the use of moAbs in children with migraine, consolidating the pivotal role of these specialists in migraine management.
Geriatrics is emerging as the fastest-growing segment in the migraine drugs industry with the highest CAGR of 12.43%, owing to the rising prevalence of migraine in older adults and better recognition of late-onset migraine. Progress in such safer and better-tolerated treatments as CGRP inhibitors lowers the increased cardiovascular risk seen with drugs we currently have. Ageing populations and broader treatment recommendations are key drivers for the growth of this underserved population.
By Availability
Prescription Drugs are the largest segment of the migraine drugs industry and register for the highest CAGR of 11.58% over the forecast period, owing to the use of clinically available therapies, including triptans, gepants, and the novel drugs related to CGRP. They do need to be used under the guidance of a physician, as they are used most effectively in long-term or severe cases. Demand is high, powered by strong physician preference plus regulatory and insurance traction behind Rxist products. The expanding range of targeted therapy also reflects the dominance of this category in migraine treatment.
Regional Analysis:
In 2024, the North American region holds the largest market share of the migraine drugs industry and dominates the market with a 45.60% market share, owing to a high disease burden, strong medical structure, and prevalent knowledge of migraine treatment. The adoption of advanced treatments at an early stage, the emergence of major pharmaceutical companies, and favorable reimbursement policies are some of the factors that contribute to the growth of the local market. A combination of high healthcare spending, clinical trials, and regulatory support of the FDA takes the market penetration of these CTC tests at full speed. Furthermore, the rise in the demand for new CGRP-based drugs and preventive treatments plays a key role in the dominance of the region in the global market for migraine medication.
Europe has a second large market for drugs due to the prevalence of migraine cases and government support for healthcare, and more awareness of early prevention of treatments. Factories producing potent pharmaceutical products, easy availability of advanced treatment, and public healthcare coverage have increased the availability of drugs in the area. Favorable reimbursement and increasing use of CGRP inhibitors are also fueling growth. Furthermore, research partnerships and multinational research programmes support Europe’s continued market presence.
Asia-Pacific emerges as the fastest-growing region with the highest CAGR of 8.28%, driven by an increase in the number of cases of migraine disorders, a rise in awareness regarding healthcare, the introduction of new products, and demand for innovative therapies in highly populated countries, including China and India. Urbanization, changing lifestyle, and stress-related diseases are imposing a greater burden of migraine. Governments are stepping up the development of healthcare infrastructure and specialty access, and big pharma is increasing funds into regional clinical development and manufacturing. The portion of novel therapies, including CGRP inhibitors and personalized medicine, is becoming more rapid. Moreover, better reimbursement policies, increased disposable income, and increasing penetration of telehealth further increase access to migraine treatment for patients. All these factors combined to make Asia Pacific one of the major growth-promoters of the market ahead.
The Middle East & Africa have the least share in the global migraine drugs market, as the region has poor healthcare infrastructure, less knowledge regarding migraine as a chronic disease, and limited availability of advanced treatment options. High cost of out-of-pocket treatments, low numbers of neurologists, and underdiagnosis are additional bottlenecks in the growth of the market. And given the regulatory obstacles and economic instability in some areas, the pharmaceutical investment is slow, leading to delayed adoption of more recent and effective migraine therapies.
The Latin American region accounts for a moderate share in the global migraine drugs market, with growing awareness, enhanced healthcare infrastructure, and growing prevalence of migraines. However, restricted access to novel treatments, high out-of-pocket expenses, and uneven health care coverage in some countries will continue to hamper more widespread market expansion. Government efforts to upgrade neurological care and increase urbanization are driving demand, however, pricing pressure and regulatory barriers are limiting the use of the latest migraine treatments in the region.
Key Players:
Migraine drugs Companies, including AbbVie Inc., Pfizer Inc., Eli Lilly and Company, Teva Pharmaceuticals, Amgen Inc., Novartis AG, Lundbeck A/S, H. Lundbeck A/S, Biohaven Ltd., Satsuma Pharmaceuticals, Zosano Pharma, Impel Pharmaceuticals, Axsome Therapeutics, Tonix Pharmaceuticals, Dr. Reddy’s Laboratories, Sun Pharma, Mylan, GSK plc, Boehringer Ingelheim, Aurobindo Pharma., and other players.
Recent Developments:
-
In March 2025, AbbVie announced the expanded global rollout of Qulipta (atogepant) for preventive migraine treatment, following positive Phase 3 results in Europe and Asia-Pacific.
-
In May 2025, Teva launched a biosimilar to fremanezumab (Ajovy) in selected Latin American markets to improve affordability and access to migraine preventive therapies.
-
In June 2024, Biohaven launched a Troriluzole Phase 2 trial for migraine prophylaxis, signaling its strategy to diversify its pipeline beyond CGRP-targeting drugs.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 6.59 billion |
| Market Size by 2032 | USD 15.54 billion |
| CAGR | CAGR of 11.34% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Treatment (Acute, Preventive) • By Route of Administration (Oral, Injectable, Others) • By Age (Pediatric, Adult, Geriatric) •By Availability (Prescription Drugs, Over-the-Counter (OTC) Drugs) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | AbbVie Inc., Pfizer Inc., Eli Lilly and Company, Teva Pharmaceuticals, Amgen Inc., Novartis AG, Lundbeck A/S, H. Lundbeck A/S, Biohaven Ltd., Satsuma Pharmaceuticals, Zosano Pharma, Impel Pharmaceuticals, Axsome Therapeutics, Tonix Pharmaceuticals, Dr. Reddy’s Laboratories, Sun Pharma, Mylan, GSK plc, Boehringer Ingelheim, Aurobindo Pharma and other players. |
Table of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Treatment
2.3.2 Market Size By Route of Administration
2.3.2 Market Size By Age
2.3.2 Market Size By Availability
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Prescription Volume Trends (2020–2032)
4.1.1 Global and regional trends in migraine drug prescriptions
4.1.2 Volume growth comparison: acute vs preventive medications
4.1.3 Trends in neurologist vs primary care prescribing patterns
4.2 Patient Demographics and Treatment Utilization (2024)
4.2.1 Gender-wise and age-wise migraine drug usAgedistribution
4.2.2 Urban vs rural prescription patterns and access
4.2.3 UsAgetrends among chronic vs episodic migraine sufferers
4.3 Drug Class and Pipeline Trends (2020–2025)
4.3.1 Market share by drug class: triptans, gepants, ditans, CGRP mAbs
4.3.2 Number of new migraine drugs approved annually (global)
4.3.3 Shift from oral drugs to injectables and nasal formulations
4.4 Access, Reimbursement, and Payer Mix (2024)
4.4.1 Insurance coverAgelevels for branded vs generic migraine drugs
4.4.2 Cost burden: out-of-pocket vs copay assistance vs public insurance
4.4.3 Impact of formulary restrictions on CGRP inhibitor uptake
4.5 Drug Pricing and Consumer Preference (2024)
4.5.1 AverAgeprice comparison of migraine drugs across brands and regions
4.5.2 Preference trends: oral vs injectable vs nasal spray formulations
4.5.3 Transparency in pricing and rise of patient discount programs
5. Migraine Drugs Market Segmental Analysis & Forecast, By Treatment, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Acute
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Preventive
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
6. Migraine Drugs Market Segmental Analysis & Forecast, By Route of Administration, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Oral
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Injectable
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Others
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
7. Migraine Drugs Market Segmental Analysis & Forecast, By Age, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Pediatric
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Adult
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
7.4 Geriatric
7.4.1 Key Trends
7.4.2 Market Size & Forecast, 2021 – 2032
8. Migraine Drugs Market Segmental Analysis & Forecast, By Availability, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Prescription Drugs
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Over-the-Counter (OTC) Drugs
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
9. Migraine Drugs Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.2.3 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.2.4 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.2.5 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.2.6 Migraine Drugs Market Size & Forecast, By Country, 2021 – 2032
9.2.6.1 USA
9.2.6.1.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.2.6.1.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.2.6.1.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.2.6.1.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.2.6.2 Canada
9.2.6.2.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.2.6.2.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.2.6.2.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.2.6.2.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3 Europe
9.3.1 Key Trends
9.3.2 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.3 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.4 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.5 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3.6 Migraine Drugs Market Size & Forecast, By Country, 2021 – 2032
9.3.6.1 Germany
9.3.6.1.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.6.1.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.1.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.6.1.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3.6.2 UK
9.3.6.2.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.6.2.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.2.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.6.2.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3.6.3 France
9.3.6.3.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.6.3.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.3.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.6.3.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3.6.4 Italy
9.3.6.4.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.6.4.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.4.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.6.4.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3.6.5 Spain
9.3.6.5.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.6.5.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.5.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.6.5.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3.6.6 Russia
9.3.6.6.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.6.6.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.6.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.6.6.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3.6.7 Poland
9.3.6.7.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.6.7.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.7.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.6.7.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.3.6.8 Rest of Europe
9.3.6.8.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.3.6.8.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.8.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.3.6.8.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.4.3 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.4 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.4.5 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.4.6 Migraine Drugs Market Size & Forecast, By Country, 2021 – 2032
9.4.6.1 China
9.4.6.1.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.4.6.1.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.1.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.4.6.1.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.4.6.2 India
9.4.6.2.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.4.6.2.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.2.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.4.6.2.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.4.6.3 Japan
9.4.6.3.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.4.6.3.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.3.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.4.6.3.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.4.6.4 South Korea
9.4.6.4.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.4.6.4.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.4.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.4.6.4.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.4.6.5 Australia
9.4.6.5.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.4.6.5.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.5.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.4.6.5.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.4.6.6 ASEAN Countries
9.4.6.6.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.4.6.6.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.6.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.4.6.6.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.4.6.7 Rest of Asia-Pacific
9.4.6.7.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.4.6.7.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.7.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.4.6.7.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.5 Latin America
9.5.1 Key Trends
9.5.2 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.5.3 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.4 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.5.5 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.5.6 Migraine Drugs Market Size & Forecast, By Country, 2021 – 2032
9.5.6.1 Brazil
9.5.6.1.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.5.6.1.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.1.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.5.6.1.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.5.6.2 Argentina
9.5.6.2.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.5.6.2.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.2.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.5.6.2.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.5.6.3 Mexico
9.5.6.3.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.5.6.3.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.3.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.5.6.3.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.5.6.4 Colombia
9.5.6.4.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.5.6.4.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.4.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.5.6.4.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.5.6.5 Rest of Latin America
9.5.6.5.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.5.6.5.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.5.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.5.6.5.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.6.3 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.4 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.6.5 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.6.6 Migraine Drugs Market Size & Forecast, By Country, 2021 – 2032
9.6.6.1 UAE
9.6.6.1.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.6.6.1.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.1.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.6.6.1.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.6.6.2 Saudi Arabia
9.6.6.2.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.6.6.2.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.2.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.6.6.2.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.6.6.3 Qatar
9.6.6.3.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.6.6.3.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.3.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.6.6.3.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.6.6.4 Egypt
9.6.6.4.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.6.6.4.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.4.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.6.6.4.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.6.6.5 South Africa
9.6.6.5.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.6.6.5.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.5.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.6.6.5.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
9.6.6.6 Rest of Middle East & Africa
9.6.6.6.1 Migraine Drugs Market Size & Forecast, By Treatment, 2021 – 2032
9.6.6.6.2 Migraine Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.6.3 Migraine Drugs Market Size & Forecast, By Age, 2021 – 2032
9.6.6.6.4 Migraine Drugs Market Size & Forecast, By Availability, 2021 – 2032
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2024
10.2.2 Year-Wise Strategies & Development, 2021 – 2025
10.2.3 Number Of Strategies Adopted By Key Players, 2024
10.3 Market Share Analysis, 2024
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6 Key Company Profiles
10.6.1 AbbVie Inc.
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 Pfizer Inc.
10.6.2.1 Company Overview & Snapshot
10.6.2.2 Product/Service Portfolio
10.6.2.3 Key Company Financials
10.6.2.4 SWOT Analysis
10.6.3 Eli Lilly and Company
10.6.3.1 Company Overview & Snapshot
10.6.3.2 Product/Service Portfolio
10.6.3.3 Key Company Financials
10.6.3.4 SWOT Analysis
10.6.4 Teva Pharmaceuticals
10.6.4.1 Company Overview & Snapshot
10.6.4.2 Product/Service Portfolio
10.6.4.3 Key Company Financials
10.6.4.4 SWOT Analysis
10.6.5 Amgen Inc.
10.6.5.1 Company Overview & Snapshot
10.6.5.2 Product/Service Portfolio
10.6.5.3 Key Company Financials
10.6.5.4 SWOT Analysis
10.6.6 Novartis AG
10.6.6.1 Company Overview & Snapshot
10.6.6.2 Product/Service Portfolio
10.6.6.3 Key Company Financials
10.6.6.4 SWOT Analysis
10.6.7 Lundbeck A/S
10.6.7.1 Company Overview & Snapshot
10.6.7.2 Product/Service Portfolio
10.6.7.3 Key Company Financials
10.6.7.4 SWOT Analysis
10.6.8 H. Lundbeck A/S
10.6.8.1 Company Overview & Snapshot
10.6.8.2 Product/Service Portfolio
10.6.8.3 Key Company Financials
10.6.8.4 SWOT Analysis
10.6.9 Biohaven Ltd.
10.6.9.1 Company Overview & Snapshot
10.6.9.2 Product/Service Portfolio
10.6.9.3 Key Company Financials
10.6.9.4 SWOT Analysis
10.6.10 Satsuma Pharmaceuticals
10.6.10.1 Company Overview & Snapshot
10.6.10.2 Product/Service Portfolio
10.6.10.3 Key Company Financials
10.6.10.4 SWOT Analysis
10.6.11 Zosano Pharma
10.6.11.1 Company Overview & Snapshot
10.6.11.2 Product/Service Portfolio
10.6.11.3 Key Company Financials
10.6.11.4 SWOT Analysis
10.6.12 Impel Pharmaceuticals
10.6.12.1 Company Overview & Snapshot
10.6.12.2 Product/Service Portfolio
10.6.12.3 Key Company Financials
10.6.12.4 SWOT Analysis
10.6.13 Axsome Therapeutics
10.6.13.1 Company Overview & Snapshot
10.6.13.2 Product/Service Portfolio
10.6.13.3 Key Company Financials
10.6.13.4 SWOT Analysis
10.6.14 Tonix Pharmaceuticals
10.6.14.1 Company Overview & Snapshot
10.6.14.2 Product/Service Portfolio
10.6.14.3 Key Company Financials
10.6.14.4 SWOT Analysis
10.6.15 Dr. Reddy’s Laboratories
10.6.15.1 Company Overview & Snapshot
10.6.15.2 Product/Service Portfolio
10.6.15.3 Key Company Financials
10.6.15.4 SWOT Analysis
10.6.16 Sun Pharma
10.6.16.1 Company Overview & Snapshot
10.6.16.2 Product/Service Portfolio
10.6.16.3 Key Company Financials
10.6.16.4 SWOT Analysis
10.6.17 Mylan
10.6.17.1 Company Overview & Snapshot
10.6.17.2 Product/Service Portfolio
10.6.17.3 Key Company Financials
10.6.17.4 SWOT Analysis
10.6.18 GSK plc
10.6.18.1 Company Overview & Snapshot
10.6.18.2 Product/Service Portfolio
10.6.18.3 Key Company Financials
10.6.18.4 SWOT Analysis
10.6.19 Boehringer Ingelheim
10.6.19.1 Company Overview & Snapshot
10.6.19.2 Product/Service Portfolio
10.6.19.3 Key Company Financials
10.6.19.4 SWOT Analysis
10.6.20 Aurobindo Pharma
10.6.20.1 Company Overview & Snapshot
10.6.20.2 Product/Service Portfolio
10.6.20.3 Key Company Financials
10.6.20.4 SWOT Analysis
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Key Segments:
By Treatment
-
Acute
-
Preventive
By Route of Administration
-
Oral
-
Injectable
-
Others
By Age
-
Pediatric
-
Adult
-
Geriatric
By Availability
-
Prescription Drugs
-
Over-the-Counter (OTC) Drugs
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
